Design, Synthesis, and Biological Evaluation of Triazolo-pyrimidine Derivatives as Novel Inhibitors of Hepatitis B Virus Surface Antigen (HBsAg) Secretion
- 25 July 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (16), 5660-5670
- https://doi.org/10.1021/jm200696v
Abstract
The high levels of hepatitis B virus (HBV) surface antigen (HBsAg)-bearing subviral particles in the serum of chronically infected individuals play an important role in suppressing HBV-specific immune response and are only mildly affected by the current small molecule therapies. Thus, a therapy that specifically reduces HBsAg serum levels could be used in combination therapy with nucleos(t)ide drugs or permit therapeutic vaccination for the treatment of HBV infection. Herein, we report the design, synthesis, and evaluation of novel triazolo-pyrimidine inhibitors (1, 3, and 4) of HBsAg cellular secretion, with activity against drug-resistant HBV variants. Extensive SAR led to substantial improvements in the EC50 of the parent compound, 5 (HBF-0259), with the best being 3c, with EC50 = 1.4 ± 0.4 μM, SI ≥ 36. The lead candidates, both 1a (PBHBV-001) and 3c (PBHBV-2-15), were well-tolerated in both normal and HBV-transgenic mice and exhibited acceptable pharmacokinetics and bioavailability in Sprague–Dawley rats.Keywords
This publication has 25 references indexed in Scilit:
- The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cellsVirology, 2009
- HBsAg inhibits TLR9-mediated activation and IFN-α production in plasmacytoid dendritic cellsMolecular Immunology, 2009
- Hepatitis B virus infectionThe Lancet, 2009
- A Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen SecretionAntimicrobial Agents and Chemotherapy, 2007
- Characterization of the Intracellular Deproteinized Relaxed Circular DNA of Hepatitis B Virus: an Intermediate of Covalently Closed Circular DNA FormationJournal of Virology, 2007
- Drug resistance in antiviral treatment for infections with hepatitis B and C virusesThe Esophagus, 2007
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to LamivudineAntimicrobial Agents and Chemotherapy, 2004
- Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudinein vivoHepatology, 1996
- Controlling hepatitis B virus transmission in North AmericaVaccine, 1990